Pharma exports: FTP promises to address problems abroad

With Indian pharma companies facing problems in exports to countries like Japan and China, the new Foreign Trade Policy seeks to address issues related to non-trade barriers and regulations faced by them abroad.

CCI suggests changes to Sun Pharma-Ranbaxy deal

The deal, which CCI has prima-facie found to be in violation of competition norms, was inked in April this year and has been awaiting clearance from the competition watchdog since then.

Pharma cos to witness 26% core sales growth in Q3: BoAML

BoAML said it sees strong base business growth at Sun, Dr Reddy, Lupin and Aurobindo Pharma.

US FDA asks Indian drugmakers to comply or face action

The US Food and Drug Administration (FDA) also warned of "appropriate action" against the companies who fail to implement "Good Manufacturing Practices".

Japanese pharma companies keen on tie-ups with Indian companies

A delegation of pharmaceutical firms from Japan's Toyama prefecture on Wednesday indicated that Japanese companies are keen to collaborate with Indian pharma companies in trade and technology development.

China major supplier of APIs to Indian pharma companies

Indian pharmaceutical industry imports majority of active pharmaceutical ingredients (APIs) and intermediates worth billions of dollars from China.

Is pharma steering India’s tryst as a major R&D hub?

While affordability is a major obstacle, Indian pharma companies’ business models based on the generic drug manufacturing business haven’t helped them to tread on the path of innovation.

Is pharma steering India’s tryst as a major R&D hub?

While affordability is a major obstacle, Indian pharma companies’ business models based on the generic drug manufacturing business haven’t helped them to tread on the path of innovation.